| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	
																	Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(2.07) per share which beat the analyst consensus estimate of ...
																	
																	
																	
																	
																	EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, underscor...
																	Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(3.16) per share which beat the analyst consensus estimate of ...